Anavex Life Sciences Corp (AVXL) - News Archive

Alzheimer s disease (AD), characterized by cognitive decline and neurodegeneration, poses a significant burden on individuals, families, and healthcare systems worldwide. The search for effective treatments has gained m...

In a significant development for Alzheimer’s disease treatment, recent findings from the ATTENTION-AD trial demonstrate that over three years of continuous treatment with oral Blarcamesine has resulted in substantial co...

In a significant advancement toward the management of Alzheimer’s disease, Blarcamesine has recently garnered acceptance for filing by the European Medicines Agency (EMA). This development positions Blarcamesine as a pr...

In a significant milestone for Alzheimer’s disease (AD) research, Anavex Life Sciences has garnered attention following the presentation of results from their landmark Phase IIb/III trial of Blarcamesine, also referred...

According to recent notices, shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL) have been urged by The Gross Law Firm for potential legal consultations concerning their rights by May 13, 2024. The exact nat...

Anavex Life Sciences Corp., a biopharmaceutical company listed on NASDAQ under the ticker AVXL, is currently facing a class action lawsuit. This article aims to provide an overview of the situation, including the key fa...

Gainey McKenna & Egleston, a New York-based law firm, has recently revealed that a class-action lawsuit has been filed against biopharmaceutical company Anavex Life Sciences Corporation (Anavex) in the United States Dis...

A Groundbreaking Progress in Neurodegenerative Disorder Treatment: Anavex Life Sciences Recent Discoveries in Clinical StudiesIn recent years, there has been growing interest in the field of neurodegenerative disorders,...

In an exciting development for the field of psychiatry, Anavex Life Sciences has recently announced the initiation of a phase 2 clinical trial for its novel investigational drug ANAVEX3-71 in the treatment of schizophre...

Anavex Life Sciences Corp. is etching its name in the annals of scientific advancements as it recently unpacked exciting updates on its Rett Syndrome Program and the topline results from its EXCELLENCE Clinical Study in...

Groundbreaking research in the field of Rett syndrome has revealed significant advancements in the form of ANAVEX2-73, a potential game-changer in treating this debilitating disorder. The recently announced clinical gen...